6 Factor VIII Concentrates, Factor VIII/von Willebrand Factor Concentrates, Factor IX Concentrates, Activated Prothrombin Complex Concentrates.
出版信息
Transfus Med Hemother. 2009;36(6):409-418.
Abstract
摘要
相似文献
1
2
3
Management of von Willebrand disease with factor VIII/von Willebrand factor concentrates: results from current studies and surveys.使用凝血因子VIII/血管性血友病因子浓缩物治疗血管性血友病：当前研究与调查结果
Blood Coagul Fibrinolysis. 2005 Apr;16 Suppl 1:S17-21. doi: 10.1097/01.mbc.0000167658.85143.49.
4
Human von Willebrand factor/factor VIII concentrates in the management of pediatric patients with von Willebrand disease/hemophilia A.人血管性血友病因子/凝血因子VIII浓缩物在儿童血管性血友病/血友病A患者管理中的应用
Ther Clin Risk Manag. 2016 Jun 30;12:1029-37. doi: 10.2147/TCRM.S87543. eCollection 2016.
5
Characterization of von Willebrand factor in factor VIII concentrates.凝血因子 VIII 浓缩物中血管性血友病因子的特性分析。
Am J Hematol. 1989 May;31(1):41-5. doi: 10.1002/ajh.2830310108.
6
Optimizing therapy with factor VIII/von Willebrand factor concentrates in von Willebrand disease.在血管性血友病中优化使用凝血因子 VIII/血管性血友病因子浓缩物进行治疗。
Haemophilia. 1998;4 Suppl 3:7-10. doi: 10.1046/j.1365-2516.1998.0040s3007.x.
7
Management of inherited von Willebrand disease.遗传性血管性血友病的管理
Best Pract Res Clin Haematol. 2001 Jun;14(2):455-62. doi: 10.1053/beha.2001.0143.
8
Pharmacokinetics and hemostatic effect of different factor VIII/von Willebrand factor concentrates in von Willebrand's disease type III.不同VIII因子/血管性血友病因子浓缩物在III型血管性血友病中的药代动力学及止血效果
Ann Hematol. 1992 Dec;65(6):253-9. doi: 10.1007/BF01836069.
9
Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.血管性血友病因子/凝血因子VIII浓缩物在血管性血友病治疗中的应用
Blood Coagul Fibrinolysis. 2009 Mar;20(2):89-100. doi: 10.1097/MBC.0b013e3283254570.
10
Treatment of von Willebrand's disease.
Mayo Clin Proc. 1991 Aug;66(8):841-6. doi: 10.1016/s0025-6196(12)61203-8.
引用本文的文献
1
Real-world insights into the management of hemophilia A in Italy: treatment patterns and healthcare resource utilization.意大利血友病A管理的真实世界见解：治疗模式与医疗资源利用
Blood Res. 2024 Oct 8;59(1):30. doi: 10.1007/s44313-024-00034-6.
2
Peptide valency plays an important role in the activity of a synthetic fibrin-crosslinking polymer.肽价在合成纤维蛋白交联聚合物的活性中起重要作用。
Biomaterials. 2017 Jul;132:96-104. doi: 10.1016/j.biomaterials.2017.04.002. Epub 2017 Apr 5.
本文引用的文献
1
Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia.预防与间歇性治疗以预防重型血友病男孩的关节疾病
N Engl J Med. 2007 Aug 9;357(6):535-44. doi: 10.1056/NEJMoa067659.
2
Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study.既往未经治疗的甲型血友病患者中抑制剂产生的治疗相关风险因素：CANAL队列研究
Blood. 2007 Jun 1;109(11):4648-54. doi: 10.1182/blood-2006-11-056291. Epub 2007 Feb 8.
3
Current use of by-passing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitors.欧洲目前在血友病和抑制剂患者急性出血管理中使用旁路制剂的情况。
Haemophilia. 2007 Jan;13(1):38-45. doi: 10.1111/j.1365-2516.2006.01403.x.
4
Options for treating acute bleeds in addition to bypassing agents: extracorporeal immunoadsorption, FVIII/FIX, desmopressin and antifibrinolytics.除旁路制剂外，治疗急性出血的其他选择：体外免疫吸附、FVIII/FIX、去氨加压素和抗纤溶药物。
Haemophilia. 2006 Dec;12 Suppl 6:62-5; discussion 65-6. doi: 10.1111/j.1365-2516.2006.01368.x.
5
Genetic risk factors for inhibitors to factors VIII and IX.凝血因子VIII和IX抑制物的遗传风险因素。
Haemophilia. 2006 Dec;12 Suppl 6:15-22. doi: 10.1111/j.1365-2516.2006.01361.x.
6
Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor.血管性血友病的病理生理学与分类更新：血管性血友病因子小组委员会报告
J Thromb Haemost. 2006 Oct;4(10):2103-14. doi: 10.1111/j.1538-7836.2006.02146.x. Epub 2006 Aug 2.
7
Continuous infusion of coagulation factors: current opinion.凝血因子的持续输注：当前观点
Curr Opin Hematol. 2006 Sep;13(5):308-15. doi: 10.1097/01.moh.0000239701.32674.e0.
8
Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors.欧洲目前在血友病及抑制物患者免疫耐受诱导治疗方面的实践。
Haemophilia. 2006 Jul;12(4):363-71. doi: 10.1111/j.1365-2516.2006.01296.x.
9
10
A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors.一项关于高剂量和标准剂量重组凝血因子VIIa治疗血友病伴抑制剂患者关节积血的前瞻性随机试验。
J Thromb Haemost. 2006 Feb;4(2):367-71. doi: 10.1111/j.1538-7836.2006.01772.x.
Zotero 插件